Vigabatrin 35years later - from mechanism of action to benefit-risk considerations

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 192, 2011, Pages 1-4

  Shields, W D ^a   Pellock, J M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aminobutyric acid; Antiepileptic drugs; Epilepsy; Review; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; VIGABATRIN; ANTICONVULSIVE AGENT;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; COMPLEX PARTIAL SEIZURE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG SYNTHESIS; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMAN; INFANTILE SPASM; IRELAND; MONOTHERAPY; NOTE; REFRACTORY COMPLEX PARTIAL SEIZURE; RISK FACTOR; UNITED KINGDOM; UNITED STATES; VISUAL FIELD DEFECT; ADULT; EDITORIAL; FOCAL EPILEPSY; HISTORY; INFANT;

ADULT; ANTICONVULSANTS; EPILEPSIES, PARTIAL; GREAT BRITAIN; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; IRELAND; SPASMS, INFANTILE; VIGABATRIN;

EID: 80855133062     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01606.x     Document Type: Note

References (31)

1. Jung MJ, Lippert B, Metcalf BW et al. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:797-802.
2. Schechter PJ, Tranier Y. Effect of elevated brain GABA concentrations on the actions of bicuculline and picrotoxin in mice. Psychopharmacology (Berl) 1977;54:145-8.
3. Grove J, Schechter PJ, Tell G et al. Increased gamma-aminobutyric acid (GABA), homocarnosine and beta-alanine in cerebrospinal fluid of patients treated with gamma-vinyl-GABA (4-amino-hex-5-enoic acid). Life Sci 1981;28:2431-9.
4. Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia 2009;50:163-73.
5. Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin Pharmacother 2009;10:3077-89.
6. Waterhouse EJ, Mims KN, Gowda SN. Treatment of refractory complex partial seizures: role of vigabatrin. Neuropsychiatr Dis Treat 2009;5:505-15.
7. Lerner JT, Salamon N, Sankar R. Clinical profile of vigabatrin as monotherapy for treatment of infantile spasms. Neuropsychiatr Dis Treat 2010;6:731-40.
8. SABRIL® Tablets [prescribing information]. Deerfield, IL: Lundbeck Inc.; 2010.
9. SABRIL® Oral Solution [prescribing information]. Deerfield, IL: Lundbeck Inc.; 2010.
10. Vigabatrin. European Summary of Product Characteristics, January 1999; (accessed 15 September 2011).
11. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314:180-1.
12. Wheless JW, Ramsay RE, Collins SD. Vigabatrin. Neurotherapeutics 2007;4:163-72.
13. Hesdorffer DC, Logroscino G, Benn EK, Katri N, Cascino G, Hauser WA. Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota. Neurology 2011;76:23-7.
14. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J Neurol Neurosurg Psychiatry 1996;61:433-43.
15. Carroll E, Benbadis SM. Complex partial seizures. 2011; (accessed 15 September 2011).
16. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
17. Sperling MR. The consequences of uncontrolled epilepsy. CNS Spectr 2004;9:98-101, 106-9.
18. Forsgren L, Hauser WA, Olafsson E, Sander JW, Sillanpaa M, Tomson T. Mortality of epilepsy in developed countries: a review. Epilepsia 2005;46(Suppl. 11):18-27.
19. Langan Y, Nashef L, Sander JW. Case control of SUDEP. Neurology 2005;64:1131-3.
20. Shields WD. Infantile spasms: little seizures, BIG consequences. Epilepsy Curr 2006;6:63-9.
21. Pellock JM, Hrachovy R, Shinnar S et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010;51:2175-89.
22. Glauser TA. Following catastrophic epilepsy patients from childhood to adulthood. Epilepsia 2004;45(Suppl. 5):23-6.
23. Ben-Menachem E. Mechanism of action of vigabatrin: correcting misperceptions. Acta Neurol Scand 2011;124(Suppl. 192):5-15.
24. Ben-Menachem E, Sander JW. Vigabatrin therapy for refractory complex partial seizures: review of major European trials. Acta Neurol Scand 2011;124(Suppl. 192):16-28.
25. Faught RE. Vigabatrin therapy for refractory complex partial seizures: review of major US trials. Acta Neurol Scand 2011;124(Suppl. 192):29-35.
26. Carmant L. Vigabatrin therapy for infantile spasms: review of major trials in Europe, Canada, and the United States; and recommendations for dosing. Acta Neurol Scand 2011;124(Suppl. 192):36-47.
27. Sergott RC, Wheless JW, Smith MC et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-opthalmology 2010;34:20-35.
28. Sergott RC, Westall CA. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin. Acta Neurol Scand 2011;124(Suppl. 192):48-56.
29. Plant GT, Sergott RC. Understanding and interpreting vision safety issues with vigabatrin. Acta Neurol Scand 2011;124(Suppl. 192):57-71.
30. Walker S, Kälviäinen R. Non-vision adverse events with vigabatrin therapy. Acta Neurol Scand 2011;124(Suppl. 192):72-82.
31. Pellock JM. Balancing the clinical benefit of vigabatrin with its associated risk of vision loss. Acta Neurol Scand 2011;124(Suppl. 192):83-91.